DK2464371T3 - Methods for preventing or treating metabolic syndrome - Google Patents

Methods for preventing or treating metabolic syndrome Download PDF

Info

Publication number
DK2464371T3
DK2464371T3 DK10808688.5T DK10808688T DK2464371T3 DK 2464371 T3 DK2464371 T3 DK 2464371T3 DK 10808688 T DK10808688 T DK 10808688T DK 2464371 T3 DK2464371 T3 DK 2464371T3
Authority
DK
Denmark
Prior art keywords
peptide
metabolic syndrome
use according
aromatic
blood
Prior art date
Application number
DK10808688.5T
Other languages
Danish (da)
English (en)
Inventor
Hazel H Szeto
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Application granted granted Critical
Publication of DK2464371T3 publication Critical patent/DK2464371T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK10808688.5T 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome DK2464371T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23327509P 2009-08-12 2009-08-12
PCT/US2010/045160 WO2011019809A1 (en) 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome

Publications (1)

Publication Number Publication Date
DK2464371T3 true DK2464371T3 (en) 2016-06-27

Family

ID=43586452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10808688.5T DK2464371T3 (en) 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome

Country Status (10)

Country Link
US (4) US20110039766A1 (enExample)
EP (4) EP2464371B1 (enExample)
JP (5) JP5909182B2 (enExample)
CN (3) CN105031605A (enExample)
CA (1) CA2770688C (enExample)
DK (1) DK2464371T3 (enExample)
ES (1) ES2576746T3 (enExample)
HK (1) HK1247820A1 (enExample)
HU (1) HUE029550T2 (enExample)
WO (1) WO2011019809A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813235A1 (en) 2009-08-24 2014-12-17 Stealth Peptides International, Inc. Methods and Compositions for Preventing or Treating Ophthalmic Conditions
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
CN102791279A (zh) * 2009-12-31 2012-11-21 康肽德生物医药技术有限公司 用于进行冠状动脉旁路移植手术的方法
AU2013237827B2 (en) * 2012-03-30 2017-12-14 Stealth Biotherapeutics Inc. Methods and compositions for the prevention and treatment neuropathy
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
EP4397314B1 (en) * 2012-10-22 2025-12-03 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
CN104994912A (zh) * 2012-12-06 2015-10-21 康肽德生物医药技术有限公司 肽治疗剂及其使用方法
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
DK2961420T3 (da) 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
JP6480921B2 (ja) * 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
EP3077049B1 (en) * 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
US10801068B2 (en) 2015-10-16 2020-10-13 The Trustees Of Columbia University In The City Of New York JAG1 expression predicts therapeutic response in NASH
AU2017249218B2 (en) * 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
TWI684459B (zh) 2016-12-15 2020-02-11 大陸商深圳瑞健生命科學研究院有限公司 一種治療動脈粥樣硬化及其併發症的方法
CN108210895A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防动脉粥样硬化及其并发症的药物及其用途
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5312899A (en) * 1988-06-30 1994-05-17 Biochem Pharma, Inc. Dermorphin analogs
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
EP1071414A1 (en) * 1998-04-24 2001-01-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
JP2003511045A (ja) * 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー Ｒｎａ結合化合物の同定方法
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
HUE027110T2 (en) * 2003-02-04 2016-08-29 Cornell Res Foundation Inc Use of an aromatic cationic peptide
KR101161823B1 (ko) * 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US20070110728A1 (en) * 2003-11-28 2007-05-17 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
CA2887797C (en) * 2004-01-23 2017-09-26 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20080125403A1 (en) * 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2947328C (en) * 2005-09-16 2019-03-05 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
US20080161400A1 (en) * 2006-10-26 2008-07-03 Xenoport, Inc. Use of forms of propofol for treating diseases associated with oxidative stress
US8088727B2 (en) * 2008-02-07 2012-01-03 Cornell University Method for reducing the risk, lessening the symptom, or delaying the onset of insulin resistance by administering SS-31
EP2262520B1 (en) * 2008-02-26 2017-05-03 Cornell University Compositions for prevention and treatment of renal injury
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE

Also Published As

Publication number Publication date
JP5909182B2 (ja) 2016-04-26
US20110039766A1 (en) 2011-02-17
HK1247820A1 (zh) 2018-10-05
JP2018052983A (ja) 2018-04-05
JP6271785B2 (ja) 2018-01-31
JP2019104768A (ja) 2019-06-27
CA2770688A1 (en) 2011-02-17
JP2017132782A (ja) 2017-08-03
CA2770688C (en) 2018-06-05
WO2011019809A1 (en) 2011-02-17
HUE029550T2 (en) 2017-03-28
EP2464371A1 (en) 2012-06-20
CN102647994A (zh) 2012-08-22
CN105031605A (zh) 2015-11-11
JP2016041762A (ja) 2016-03-31
CN107412724A (zh) 2017-12-01
EP2464371B1 (en) 2016-03-16
US20160199435A1 (en) 2016-07-14
EP3427746A1 (en) 2019-01-16
US20180104304A1 (en) 2018-04-19
US20190209641A1 (en) 2019-07-11
EP2464371A4 (en) 2013-02-20
ES2576746T3 (es) 2016-07-11
JP2013501802A (ja) 2013-01-17
EP3067061A1 (en) 2016-09-14
EP3251686A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
DK2464371T3 (en) Methods for preventing or treating metabolic syndrome
US12102659B2 (en) Methods for the prevention or treatment of heart failure
JP2019069985A (ja) ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
HK1224948A1 (en) Methods for preventing or treating metabolic syndrome
HK1242194A1 (en) Methods for preventing or treating metabolic syndrome
HK1174844A (en) Methods for preventing or treating metabolic syndrome
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis